Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-05
2008-08-19
Weddington, Kevin E (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S558000, C514S724000, C514S866000
Reexamination Certificate
active
07414044
ABSTRACT:
A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with diabetes and obesity.
REFERENCES:
patent: 4451480 (1984-05-01), DeVillez
patent: 4591602 (1986-05-01), DeVillez
patent: 4983637 (1991-01-01), Herman
patent: 5086076 (1992-02-01), Herman
patent: 5126376 (1992-06-01), Herman
patent: 5190977 (1993-03-01), Herman
patent: 5190979 (1993-03-01), Herman
patent: 5260342 (1993-11-01), Herman
patent: 5270344 (1993-12-01), Herman
patent: 5364879 (1994-11-01), Herman
patent: 6187333 (2001-02-01), Murad et al.
patent: 6784207 (2004-08-01), Fluehmann et al.
patent: 6790463 (2004-09-01), Hofmann et al.
patent: 6884797 (2005-04-01), Hofmann
patent: 2002/0082298 (2002-06-01), Fluehmann et al.
patent: 2002/0177585 (2002-11-01), Hofmann et al.
patent: 2003/0032677 (2003-02-01), Hofmann
patent: 2005/0110484 (2005-05-01), Hofmann
patent: 2006/0002302 (2006-01-01), Hofmann
National Diabetes Information Clearinghouse (NDIC), http://diabetes.niddk.nih.gov/dm/pubs/overview/index.htm. (2007).
Cortez, M., C. Torgan, J. J. Brozinick, and J. Ivy. Insulin resistance of obese Zucker rats exercise trained at two different intensities. Am. J. Physiol 261: E613-619, 1991.
Crettaz, M., M. Prentki, D. Zaninetti, and B. Jeanrenaud. Insulin resistance in soleus muscle from obese Zucker rats: Involvement of several defective sites. Biochem. J. 186: 525-534, 1980.
Ivy, J.L., T.W. Zderic, and D.L. Fogt. Prevention and treatment of non-insulin-dependent diabetes mellitus. E.S.S.R. vol. 27, 1-35, 1999.
Ivy, J., W. Sherman, C. Cutler, and A. Katz. Exercise and diet reduce muscle insulin resistance in obese Zucker rat. Am. J. Physiol 251: E299-305, 1986.
Maritim A.C., R.A. Sanders, J.B. Watkins 3rd. Diabetes, oxidative stress, and antioxidants: A review. J. Biochem. Mol. Toxicol. 17: 24-38, 2003.
Sherman, W., A. Katz, C. Cutler, R. Withers, and J. Ivy. Glucose transport: locus of muscle insulin resistance in obese Zucker rats. Am. J. Physiol. 255: E374-382, 1988.
Zucker, L.M. and H.N. Antoniades. Insulin and obesity in the Zucker genetically obese Rat “fatty.” Endocrinology 90: 1320-1330, 1972.
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration dated Sep. 9, 2006.
Jackson Walker L.L.P.
Weddington Kevin E
LandOfFree
Use of targeted oxidative therapeutic formulation in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of targeted oxidative therapeutic formulation in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of targeted oxidative therapeutic formulation in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4000026